MEHMET ÇİTİL, HİDAYET METİN ERDOĞAN, Edoğan UZLU, EMİNE ATAKİŞİ, VEHBİ GÜNEŞ, MEHMET TUZCU, METEHAN UZUN, ABDULLAH DOĞAN

Protective effects of L-carnitine on doxorubicine induced cardiomyopathy in rabbits

Bu çalışmada Doksorubisinin (DOX) kalp dokusunda oluşturacağı yan etkiler üzerine L-karnitinin (LCAR) koruyucu etkilerinin araştırılması amaçlanmıştır. Bu amaçla, çalışmada toplam 21 adet sağlıklı albino Yeni Zelanda tavşanı üç ayrı grup oluşturularak kullanıldı. Grup I’deki tavşanlara (n=8) 0.6mg/kg canlı ağırlık (CA) dozda DOX, Grup II’deki tavşanlara (n=7) 0,6mg/kg CA dozda DOX ile 1000 mg/kg CA dozda LCAR İP, Grup III’teki tavşanlara (n=6) 1000mg/kg CA dozda LCAR İP yolla günde bir kez 6 gün süreyle uygulandı. Bütün hayvanlardan kan örneklerinin toplanması ilk ilaç kullanımından önce ve 6 gün boyunca ilaç uygulamasını takiben 2 saat sonra gerçekleştirildi. Çalışma sonunda tüm hayvanlardan patolojik değerlendirmeler için numuneler alındı. Yalnızca DOX grubundaki tavşanların kalp dokularında makroskobik ve mikroskobik değişimler belirlendi. Çalışma süresince ve tüm gruplardaki hayvanlarda kardiyak troponin-I ve T rapid assay testleri negatif olarak tespit edildi. Çalışmanın 0. gününde tüm gruplardaki hayvanlardan elde edilen biyokimyasal değerler arasında anlamlı bir farklılık belirlenmezken, çalışmanın ilerleyen günlerinde istatistiksel olarak farklılıklar tespit edildi. DOX grubundaki hayvanlardan elde edilen troponin-I düzeyleri ile CK-MB ve LDH enzim aktiviteleri LCAR kullanılan gruplarla karşılaştırıldığında istatistiksel olarak yüksek olduğu belirlendi. Histopatolojik ve biyokimyasal analiz sonuçları, parenteral LCAR uygulamalarının doksorubisinin kalp dokusu üzerindeki yan etkilerine karşı koruyucu etkilere sahip olduğunu göstermektedir.

Anahtar Kelimeler:

tavşan, antineoplastik ajanlar, kardiyomiyopati, doksorubisin, deney hayvanları, troponin

Tavşanlarda doksorubisinle oluşturulan kardiyomiyopatilerde L-karnitinin koruyucu etkileri

This study was aimed to investigate effect of L-carnitine (LCAR) on adverse effect of doxorubicin (DOX) on heart tissues. For this purpose, a total of 21 healthy albino New-Zealand rabbits were divided into 3 groups. Rabbits in group I (n=8) received DOX at a dose rate of 0.6 mg/kg/day body weight (BW) intra peritoneally (IP) for 6 days, group II (n=7) received DOX at a dose rate of 0.6 mg/kg/day BW, IP and LCAR at dose of 1000 mg/kg/day BW IP for 6 days and group III /n=6) received LCAR at dose of 1000 mg/kg/day BW IP for 6 days. Blood samples from auricular vein were taken from all animals at the beginning of the experiment (before drug administration) and 2 hours after drug administration daily for 6 days. Pathological examination of all animals was carried out at the end of the study. Macroscopic and microscopic alterations were noticed only in heart of the DOX-group rabbits. Cardiac troponin-I and T rapid assay tests of animals in all groups were negative throughout the study. There were no statistically significant changes in biochemical parameters on day 0 between the groups, while on subsequent days these parameters altered. Blood concentrations of troponin-I, CK-MB and LDH were significantly higher in DOX received group when compared to the groups given LCAR. The results of histopathological and biochemical analysis reveal that parenteral LCAR administration had a protective effect against adverse effect of DOX on heart and kidney.

Keywords:

rabbits, antineoplastic agents, cardiomyopathy, doxorubicin, laboratory animals, troponins,

PDF

___

De Leonardis V, Neri B, Bacalli S, Cinelli P: Reduction of cardiac toxicity of anthracyclines by L-carnitine. Int J Clin Pharmacol Res, 5, 137-142, 1985.
Mortensen SA, Olsen HS, Baandrup U: Chronic anthracycline cardiotoxicity: Haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J, 55 (3): 274-282, 1986.
Shug AL: Protection from adriamycine-induced cardiomyopathy in rats. Z Kardiol, 76, 46-52, 1987.
Dorr RT: Cytoprotective agents for anthracycline. Semin Oncol, 23, 23-34, 1996.
Zhang J, Clark JR, Herman EH, Ferrans VJ: Doxorubicininduced apoptosis in spontaneously hypertensive rats: Differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol, 28, 1931-1943,1996.
Regitz-Zagrosek V, Fleck E: Myocardial carnitine deficiency in human cardiomyopathy. In, De Jong JW, Ferrari R (Eds): The carnitine system-A new therapeutically approach to cardiovasculer Diseases. 145-166, Kluwer Academic Publisher, Dordrecht, 1995.
York CM, Cantrell CR, Borum PR: Cardiac carnitine deficiency and altered carnitine transport in cardiomyopathic hamsters. Arch Biochem Biophys, 221, 526-531,1983.
Gurtler AK, Löster H: Carnitine und seine Bedeutung bei der Pathogenese und Therapie von Herz- und Kreislauferkrankungen. Ponte Press, Bochum, 1996.
Suzuki Y, Kamikawa T, Kobayashi A, Yamazaki N: Effect of L-carnitine on tissue levels of free fatty acids, acyl-CoA, and acylcarnitine in ischemic heart. Adv Myocardiol, 4, 549-557, 1983.
Kobayashi A, Masumura Y, Yamazaki N: L-carnitine treatment for congestive heart failure-experimental and clinical study. Jpn Circ J, 56 (1): 86-94, 1992.
Rice MS: Appropriate roles of cardiac troponins in evaluating patients with chest pain. J Am Board Fam Practice, 12, 214-218, 1999.
Jurlander B, Clemensen P, Wagner GS, Grande P: Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase-MB. Eur Heart J, 21, 382-389, 2000.
Azzazy HME, Christenson RH: Cardiac markers of acute coronary syndrome: Is there a case for point-of-care testing? Clin Biochem, 35, 13-27, 2002.
Christenson RH, Apple FS, Morgan DL, Alonsozona GL, Mascotti K, Olson M, McCormack RT, Wians FH, Keffer JH, Duh SH: Cardiac troponin-I measurement with the Access immunoassay system: Analytical and clinical performance characteristics. Clin Chem, 44, 52-60, 1998.
Boccara G, Pouzeratte Y, Troncin R, Bonardet A, Boularan AM, Colson P, Mann C: The risk of cardiac injury during laparoscopic fundoplication, Cardiac troponin-I and ECG study, Acta Anaesthesiol Scand, 44, 398-402, 2000.
Ooi DS, Isotalo PA, Veinot JP: Correlation of antemortem serum creatine kinase-MB, troponin-I and troponin-T with cardiac pathology. Clin Chem, 46, 338-344, 2000.
Bertsch T, Bleuel H, Aufenanger J, Rebel W: Comparison of cardiac troponin-T and cardiac troponin-I concentrations in peripheral blood during orciprenaline induced tachycardia in rats. Exp Toxicol Pathol, 49, 467-468, 1997.
Panteghini M: Present issues in the determination of troponins and other markers of cardiac damage. Clin Biochem, 33, 161-166, 2000.
M-Bardorff M, Hallermayer K, Schro A, Ebert C: Improved troponin-T ELISA specific for cardiac troponin-T isoform: Assay development and analytical and clinical validation. Clin Chem, 43, 458–466, 1999.
O’Brien PJ, Landt Y, Ladenson JH: Differential reactivity of cardiac and skeletal muscle from various species in a cardiac troponin-I immunoassay. Clin Chem, 43, 2333–2338, 1997.
Charles CJ, Elliott JM, Nicholls MG, Rademaker MT, Richards M: Myocardial infarction with and without reperfusion in sheep: Early cardiac and neurohumoral changes. Clin Sci, 98, 703-711, 2000.
Fredericks S, Merton GK, Lerena MJ, Heining P, Carter ND, Holt DW: Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clin Chim Acta, 304, 65-74, 2001.
Ricchiuti V, Sharkey SW, Murakami MM, Voss EM, Apple FS: Cardiac troponin-I and T alterations in dog hearts with myocardial infarction: Correlation with infarct size. Am J Clin Pathol, 110 (2): 241-247, 1998.
Sleeper MM, Clifford CA, Laster LL: Cardiac troponin-I in the normal dog and cat. J Vet Int Med, 15 (5): 501-503, 2001. Shaw SP, Rozanski EA, Rush JE: Cardiac troponins-I and T in dogs with pericardial effusion. J Vet Int Med, 18, 322-324, 2004.
Gunes V, Erdogan HM, Citil M, Ozcan K: Use of cardiac troponins in the diagnosis of myocardial degeneration due to Foot and Mouth Disease in a calf. Vet Rec, 156 (22):714–715, 2005.
Adin DB, Oyama MA, Sleeper, MM, Milner, RJ: Comparison of canine cardiac troponin-I concentrations as determined by 3 analyzers. J Vet Int Med, 20, 1136-1142,2006.
Gunes V, Atalan G, Citil M, Erdogan M: The use of cardiac troponin kits in determination of myocardial degeneration in cattle with traumatic reticulo pericarditis. Vet Rec,162 (16): 514-517, 2008.
Tunca R, Sozmen M, Erdogan HM, Citil M, Uzlu E, Ozen H, Gokce E: Determination of cardiac troponin-I in the blood and heart of calves with Foot-and-Mouth Disease. J Vet Diag Invest, 20 (5): 598-605, 2008.
Tunca R, Erdogan HM, Sozmen M, Citil M, Devrim AK, Erginsoy S, Uzlu E: Evaluation of cardiac troponin-I and inducible nitric oxide synthase expressions in lambs with White Muscle Disease. Turk J Vet Anim Sci, 32 (2): 2008,(In press).
Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, Burdy JY, Fabbro-Peray P, Laprade M, Bali JP, Granier C, De la Coussaye JE, Dauzat M: Evaluation of cardiac troponin-I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta, 329, 39-51, 2003.
Teraoka K, Hirano M, Yamaguchi K, Yamashina A: Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail, 2, 373-378, 2000.
Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA: Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol, 31, 1435-1446, 1999.
Kumar D, Kirshenbaum L, Li T, Danelisen I, Singal P: Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann NY Acad Sci, 874, 156-168, 1999. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB: Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res, 61, 771-7, 2001.
Caulfield JB, Bittner V: Cardiac matrix alterations induced by adriamycin. Am J Pathol, 133, 298-305, 1998.
Bremer J: Carnitine metabolism and functions. Physiol Rev, 63, 1420-1480, 1983.
Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ: L-carnitine prevents doxorubicininduced apoptosis of cardiac myocytes: Role of inhibition of ceramide generation. FASEB J, 13, 1501-1510, 1999.
Di Marzio L, Alesse E, Roncaioli P, Muzi P, Moretti S, Marcellini S, Amicosante G, De Simone C, Cifone MG: Influence of L-carnitine on CD95 cross-linking-induced apoptosis and ceramide generation in human cell lines: Correlation with its effects on purified acidic and neutral sphingomyelinases invitro. Proc Assoc Am Physicians, 109, 154-163, 1997.
Kawasaki N, Lee JD, Shimizu H, Ueda T: Long-term Lcarnitine treatment prolongs the survival in rats with adriamycin-induced heart failure. J Cardiac Failure, 2, 293- 299, 1996.
Neri B, Cini-Neri G, Bartalucci S, Bandinelli M: Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro. Anticancer Res, 6, 659-662, 1986.
Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Annu Rev Physiol, 60, 643-665,1998.
Giuliani I, Bertinchant JP, Lopez M, Coquelin H, Granier C, Laprade M, Paul B, Larue C: Determination of cardiac troponin-I forms in the blood of patients with unstable angina pectoris. Clin Biochem, 32, 111-117, 2002.
Whitehead CC, McCormack HA, McTeir L: Effects of dietary carnitine supplementation on susceptibility of chicks to ascites induced cold stress. Res Report, 1997.
Fritz IB, Arrigoni-Martelli E: Sites of action of carnitine and its derivatives on the cardiovasculer system, interactions with membranes. Trend Pharmacol Sci, 14, 355-360, 1993.
Uhlenbruck G: L-carnitine and the immune system: from the mode of metabolism to the modulation of membranes. In, Seim H, Löster H. (Eds): L-carnitine–Pathochemical basics and clinical applications. 47-60, Ponte Press, Bochum, 1996.
Arcamone F, Franceschi G, Tenco S, Selva S: Adriamycin (14-hydroxidaunorubucin), a novel antitumor antibiotic. Tetrahedron Lett, 13, 1007-1010, 1969.
Sayed-Ahmed MM, Salman TM, Gaballah HE, Abou El- Naga SA, Nicolai R, Calvani M: Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res, 43, 513-520, 2001.